Background: Adaptive servo-ventilation (ASV) is used to treat heart failure (HF).
Introduction
Sleep-disordered breathing (SDB) has a close relation to heart failure (HF), the incidence of fatal cardiovascular events, and mortality [1] . Adaptive servo-ventilation (ASV) therapy has been shown to be effective for central sleep apnea (CSA) and Cheyne-Stokes respiration (CSR) [2, 3] . Recently, ASV therapy has also been used to treat patients with HF who also have CSA and CSR [2, 4, 5] as well as patients with SDB, including those with obstructive sleep apnea [6, 7] . Previously, we reported that ASV therapy for patients with mild SDB resulted in almost equal improvements in brain natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF) compared with patients with moderate and severe SDB, thus demonstrating that ASV therapy was effective for all patients with HF [8] . However, previous reports have suggested that there is a negative relationship between the severity of SDB and prognosis [1, 9] . It remained unclear as to whether ASV could improve the long-term prognosis of patients with HF, regardless of the severity of SDB.
We aimed to clarify whether ASV therapy improved the short-and long-term prognosis in patients with HF, regardless of the severity of SDB. We hypothesized that both the short-and long-term prognosis of patients with HF could be improved by improving their SDB.
Methods

Study design and ethical considerations
The present study was a single-center, prospective cohort study of HF patients We included 61 consecutive patients with HF who were initiated on ASV therapy after polysomnography to screen for SDB. All patients had a history of HF, such as, coronary artery disease, valvular disease, and cardiomyopathy, and were classified into class II-IV, according to the criteria of the New York Heart Association.
All patients were treated with optimal medical therapy for HF before undergoing full-night polysomnography and were prescribed ASV therapy. For analysis, patients were classified into the following three groups based on the apnea-hypopnea index (AHI): a severe group with an AHI of ≥40/h (n = 28); a moderate group with an AHI of ≥20/h but <40/h (n = 20); and a mild group with an AHI of <20/h (n = 13). To estimate long-term prognosis, we reviewed the 3-year follow-up data, including that concerning fatal cardiovascular events (death from myocardial infarction, cardio-embolic stroke, and fatal cardiac arrhythmias).
Sleep evaluation and treatment devices
We conducted full-night polysomnography to analyze SDB for all patients with HF, using a digital polygraph (P-Series Plus; Compumedics, Abbotsville, Australia) according to a commonly used method. We measured nasal airflow with an airflow pressure transducer, arterial oxygen saturation by pulse oximetry with a finger probe (Nonin 8000J Adult Flex Sensor), and chest and abdominal movement using two bands (inductive respiratory bands), an electroencephalogram, an electrooculogram, and a chin electromyogram. We scored sleep staging and arousal according to generally accepted definitions and methods [10] [11] [12] .
After confirmation of SDB and grading of severity by full-night polysomnography, we used an ASV device (AutoSet-CS; ResMed, Sydney, Australia) with 6 a full facemask (ResMed) for all HF patients. We set the expiratory positive airway pressure at 4 cm H 2 O and the inspiratory support pressure at 3-8 cm H 2 O. The backup respiratory rate for apnea or hypopnea was 15 breaths/min. We checked patient compliance with ASV therapy from the ASV device. If apnea or hypopnea was observed, the ASV device modified the expiratory positive airway pressure and inspiratory support to fit the patients' breathing as necessary.
Data collection
We defined underlying heart disease as ischemic cardiomyopathy, valvular heart disease, and cardiomyopathy. Patients with ischemic cardiomyopathy were defined as those with angina pectoris, unstable angina pectoris, or acute coronary syndrome by coronary angiography in the past. Patients with valvular heart disease were defined as those with uncontrolled refractory HF after surgery for valvular heart disease or those with HF induced by valvular heart disease but without an indication for surgery. Patients with cardiomyopathy were defined as those with dilated or hypertrophic cardiomyopathy.
We defined coronary risk factors as hypertension, dyslipidemia, and diabetes mellitus. Hypertension was defined as a blood pressure ≥140/90 mmHg or the use of antihypertensive medication. Dyslipidemia was defined as elevated low-density-lipoprotein cholesterol (≥120 mg/dL), reduced high-density-lipoprotein cholesterol (<40 mg/dL), triglycerides ≥150 mg/dL, or the use of antilipidemic drugs. Diabetes mellitus was defined as a fasting blood sugar ≥126 mg/dL and an HbA1c ≥6.5%, or the use of insulin or oral antihyperglycemic drugs.
Transthoracic echocardiography was performed to evaluate the LVEF in all patients before ASV therapy; LVEF was calculated by the modified Simpson's method.
We also took a blood sample to evaluate the BNP level before ASV therapy. BNP and LVEF were then re-evaluated 6 months after ASV therapy to assess the effect on 7 short-term prognosis. We also used LVEF and BNP to evaluate the severity of HF between patients with fatal cardiovascular event.
Outcomes
The primary endpoint was fatal cardiovascular mortality at 3 years, defined as death from myocardial infarction, cardioembolic stroke, or fatal cardiac arrhythmias. We excluded patients with non-cardiac fatal events.
Statistical analysis
All values are shown as mean ± standard deviation (SD) or median (25%-75% inter-quartile range). Normally distributed data were evaluated by Fisher's exact test for binary variables or by one-way analysis of variance for continuous variables.
Non-normally distributed data were evaluated by the χ 2 test for binary variables or by the Kruskal-Wallis test for continuous variables. The log-rank test was used to compare the fatal cardiovascular event-free rate among the three groups. Repeated-measures analysis of variance was used to evaluate whether ASV therapy improved BNP and LVEF among the three AHI groups. We considered P-values <0.05 to be significant in all comparisons. All statistical analyses were conducted using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan). EZR is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) with a modified version R command designed to add statistical functions that are used frequently in biostatistics. Table 1 shows the patient characteristics before ASV therapy. We enrolled 61 patients in this study and classified them into three groups by the severity of SDB. No significant differences were apparent among the three groups with respect to age and gender, body mass index, BNP, and LVEF. The mean age was 70 ± 10 years and men accounted for the majority of participants (68.9%). The median BNP levels before ASV therapy were as follows: 379 (260-503) pg/ml in the mild group, 590 (187-560) pg/ml in the moderate group, and 488 (202-629) pg/ml in the severe group (P = 0.481). The mean LVEFs before ASV therapy were as follows: 46.2% ± 17.2% in the mild group, 43.9% ± 17.2% in the moderate group, and 44.1% ± 17.9% in the severe group (P = 0.917). Table 2 shows the results of full-night polysomnography before ASV therapy.
Results
Characteristics of patients
Sleep study
There were no significant differences in the total sleeping time or sleep efficacy among the three groups. As expected though, significant differences did exist in the arousal index, AHI, CSA index, and obstructive sleep index, which were positively correlated with the severity of SDB. Figure 1 shows the Kaplan-Meier survival curves for the fatal cardiovascular event-free rate among the three groups by SDB severity. After the 3-year follow up, no significant difference was observed in the risk of fatal cardiovascular events (log-rank test: P = 0.207). ASV therapy was effective for all patients, regardless of the severity of SDB.
Fatal cardiovascular event-free rate
The differences between patients with fatal cardiovascular events and those with non-fatal cardiovascular events are summarized in Table 3 . No significant differences were observed by age and gender, BNP, LVEF, or AHI between those with and without fatal cardiovascular events.
Improvement of LVEF and BNP level
The BNP level and LVEF were improved almost equally in the three groups after ASV treatment ( fig. 2) . Although the BNP level decreased significantly in each group from before to after ASV therapy (changes of BNP levels: mild group, 146 [25-240] pg/ml; 9 moderate group; 286 [4.97-289] pg/ml; and severe group, 348 [82-509] pg/ml), there was no significant difference among the three groups (P = 0.339). Similarly, although the LVEF increased significantly in each group from before to after ASV therapy (changes of LVEF: mild group, 8.83% ± 11.9%; moderate group; 12.5% ± 12.0%; and severe group;
8.11% ± 12.5%), there was no significant difference among the three groups (P = 0.491).
Discussion
Findings and Data interpretation
In this study, we found that ASV therapy improved both the short-and long-term prognosis of patients with HF, regardless of the severity of SDB.
First, ASV therapy improved the long-term prognosis for patients with HF, regardless of SDB severity. To our knowledge, there are no reports on this relationship between the effects of ASV therapy and SDB severity. Although it is well known that the prognosis of patients is negatively correlated with the severity of SDB [9] , little has been reported on the long-term prognosis in patients with HF after initiating ASV therapy.
Earlier, we showed that ASV therapy was effective for patients with HF and that it improved their prognosis after one year [13] . Furthermore, Yoshihisa et al. reported that ASV therapy improved the long-term prognosis of patients with chronic HF and CSR for about 3 years, and that of patients with HF, preserved LVEF, and SDB for about 4 years [14, 15] . Similar research also suggested that ASV therapy could improve the prognosis of patients with HF and comorbid chronic kidney disease and SDB [16] . However, the present report differs from those reports [13] [14] [15] [16] in that we evaluated the relationship between long-term prognosis and SDB severity. Indeed, we found improved long-term prognosis regardless of SDB severity in a larger cohort (n = 61) than previously reported. Second, ASV therapy for patients with HF improved the short-term prognosis, as determined by improvements in LVEF and BNP, regardless of the severity of SDB.
Previously, we reported that ASV treatment for patients with mild SDB resulted in comparable improvements in BNP and LVEF to those for patients with moderate and severe SDB [8] . Koyama et al. have also reported that ASV therapy for patients with HF effectively improved the short-term prognosis (again, assessed by LVEF and BNP), irrespective of the SDB severity [17] . Moreover, previous reports have revealed that ASV therapy improved both BNP and LVEF [2, 3, 17, 18] . The results of the present study are therefore consistent with previous findings.
ASV therapy is usually used to treat CSA and CSR [2, 3] . However, ASV therapy increasingly appears to be appropriate for the management of all patients with HF because it improves both the short-and long-term prognosis, regardless of the severity of SDB.
ASV therapy is therefore an effective non-pharmacological therapy for all patients HF, which is particularly relevant given that patients with SDB have a poorer prognosis than those without SDB [1, 9] .
Limitation
The present study has two main limitations. First, this study was observational rather than randomized. The cohort may be biased by being enrolled from a single center; however, we made efforts to reduce this bias by applying ASV therapy to consecutive patients. Second, our study population was small. The results will therefore need to be confirmed in a larger clinical trial.
Conclusion
11
In conclusion, this study clearly revealed that ASV therapy for patients with HF improved both the short-and long-term prognosis, regardless of the severity of SDB. Our results suggest that ASV therapy is associated with a good prognosis and is effective for all patients with HF and SDB.
Figure Legends
Figure. 1
Kaplan-Meier estimates of the fatal cardiovascular event-free rate by the severity of sleep-disordered breathing (SDB). SDB was classified as mild (apnea-hypopnea index
[AHI] <20) moderate (AHI ≥20, but <40), and severe (AHI ≥40). The AHI was the mean number of apnea and hypopnea episodes per hour during sleep. The total sample included 61 patients with HF. Log-rank test for differences in fatal cardiovascular events, P = 0.207.
Figure. 2
Comparison of the brain natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF) before and after adaptive servo-ventilation (ASV) therapy among patients with mild (apnea-hypopnea index [AHI] <20) moderate (AHI ≥20, but <40), and severe (AHI 
